Joben Bio-Medical Co Ltd is a Taiwan-based company mainly engaged in the development and sale of new plant medicines, local Chinese herbal medicines, health foods and medical beauty products. The Company develops JBM-TC4 plant new drug, which has been patented, used to provide raw materials for cancer treatment drugs.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Taipei Exchange Other stock markets 18/10/2019			5-day change	1st Jan Change
10.50 ^TWD	+0.96%		+8.81%	-

13/08/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	CI
15/04/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	CI

Market Cap	641M 20.69B 554M 518M 475M 893M 60.98B 907M 6.07B 2.38B 30.57B 2.41B 2.35B 101B	P/E 2017	53.5x	P/E 2018	-22.8x
Enterprise Value	867M 28.01B 750M 701M 643M 1.21B 82.56B 1.23B 8.22B 3.23B 41.38B 3.26B 3.19B 137B	EV / Sales 2017	5.87x	EV / Sales 2018	15.8x
Free-Float	82.63%	Yield 2017	0.07%	Yield 2018	-

13/08/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	CI
15/04/19	Joben Bio-Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	CI

Director	Title	Age	Since
Wen Tien Huang CHM	Chairman	-	20/05/2010
Man Hsia Chia BRD	Director/Board Member	-	20/05/2010
Chao Yuan Kuo BRD	Director/Board Member	-	24/06/2011

JBM Stock

Stocks

4193

TW0004193008

Biotechnology & Medical Research

Valuation: JBM

Latest news : JBM

Quotes and Performance

Managers and Directors: JBM

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JBM	+0.96%	+8.81%	-	-	21.03M
LONZA GROUP AG	+0.31%	+2.43%	+6.02%	+15.20%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+592.61%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+73.63%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.15%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+47.53%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+122.50%	16.49B
EUROFINS SCIENTIFIC SE	-0.26%	+2.78%	+5.07%	+18.08%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+23.95%	12.77B
Average	+1.92%	+6.57%	+85.85%	+112.83%	26.49B
Weighted average by Cap.	+2.41%	+6.10%	+105.33%	+137.91%

	2017	2018
Net sales	554M 17.89B 479M 448M 411M 772M 52.73B 784M 5.25B 2.06B 26.43B 2.08B 2.03B 87.37B	192M 6.21B 166M 155M 143M 268M 18.31B 272M 1.82B 716M 9.18B 723M 707M 30.34B
Net income	60.66M 1.96B 52.47M 49M 44.95M 84.54M 5.77B 85.89M 575M 226M 2.89B 228M 223M 9.57B	-123M -3.98B -107M -99.62M -91.39M -172M -11.74B -175M -1.17B -459M -5.88B -463M -453M -19.45B
Net Debt	2.35M 75.86M 2.03M 1.9M 1.74M 3.27M 224M 3.33M 22.26M 8.74M 112M 8.82M 8.63M 370M	227M 7.32B 196M 183M 168M 316M 21.58B 321M 2.15B 843M 10.82B 851M 833M 35.76B